When is adalimumab indicated in the treatment of hidradenitis suppurativa (HS)?

Updated: Aug 30, 2019
  • Author: Marina Jovanovic, MD, PhD; Chief Editor: William D James, MD  more...
  • Print
Answer

If the patient is not improved, then adalimumab is recommended as a first-line treatment option in patients with moderate-to-severe hidradenitis suppurativa who were unresponsive to or intolerant of oral antibiotics. Dosing is adalimumab 160 mg at week 0, 80 mg at week 2, and then 40 mg subcutaneously weekly.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!